Search Browse Earnings

Opus Genetics, Inc.

Nasdaq:IRD

Pharmaceutical Preparations·DURHAM, NC

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Opus Genetics, Inc. — SlamSEC

Revenue

$11.0M

-42.3% YoY

FY 2025

Adj. EBITDA

-$62.0M

-564.3% margin

FY 2025

Net Income

-$57.5M

-523.4% margin

FY 2025

EPS (Diluted)

-$2.15

FY 2025

Stock Price

$5.04

+0.5%

2026-03-13

52W Range

$0.65 – $5.30

P/E Ratio

-2.3x

Market Cap

$358.2M

Cash

$30.3M

FY 2025

Total Debt

$600,000

FY 2025

Net Cash

$29.7M

FY 2025

Enterprise Value

$328.5M

Debt / EBITDA

0.5x

FY 2025

EV / EBITDA

-5.3x

Employees

—